VRTX - 3 Growth Stocks That Are Crushing It This Year
The biotech sector has had a challenging year so far. The SPDR S&P Biotech ETF is still down more than 26%, and the iShares Biotechnology ETF is down more than 19%, even though both have rallied a bit in the past few months.
Contrast that with Vertex Pharmaceuticals (NASDAQ: VRTX) , Axsome Therapeutics (NASDAQ: AXSM) , and Neurocrine Biosciences (NASDAQ: NBIX) , as all are up 20% or more this year. Their momentum is likely to continue because all three biotech companies have blockbuster drugs and large, late-stage pipelines that could pay off for years to come.
Vertex Pharmaceuticals specializes in treating cystic fibrosis (CF), a rare genetic condition that affects the lungs, pancreas, and other organs. The company has had a big year financially and in terms of drug development, and the shares are up more than 32% in 2022.
For further details see:
3 Growth Stocks That Are Crushing It This Year